| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Insulet Corporation$166.25
+6.97 (+4.38%)
D 34Pipeline Score MedTech · Commercial
Market Cap
10.73 B
EPS
4.31
P/E Ratio
36.05 $
Value Trade
163.24 M
SEC Financials
Q1 2026Dilution Risk
Revenue
761.70 M
R&D Expenses
89.70 M
Operating CF
113.80 M
Total Assets
2.99 B
Total Liabilities
1.68 B
Equity
1.30 B
D/E Ratio
12,345
3.32 %
Week
-19.62 %
1 Month
-36.96 %
3 Month
-51.9 %
6 Month
-39.07 %
5 Year
811 %
All Time
Cash Data
Cash Position
480.40 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
595.05 K
52 Week Range
145.59 - 354.88
% held by Insiders
0.43 %
% held by Institutions
104.9 %
Enterprise Value
11.19 B
Total Shares
69.25 M
Short %
7.04 %
Float Shares
68.97 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Insulet Corporation
1Total events
1Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D34
Pipeline Score $45M
Pipeline ValueValuation Signal
1
Drugs Scored0.0x
rNPV / MCap Top 44%
Mid Cap (rank 512 of 912)
Percentile RankInsulet Corporation faces pipeline headwinds (34/100), with $53M risk-adjusted pipeline value, led by Multiple daily injections of insulin in Type 1 Diabetes (Unknown), across $60B in total addressable markets.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PODD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PODD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PODD▲ +4.4%today
Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss
Insulet Corporation has partnered with Calm to provide emotional well-being resources for individuals living with diabetes. This collaboration marks Calm's first integrated content partnership with a MedTech company, aiming to support patients, caregivers, and healthcare professionals. The initiative includes mindfulness tools and a new sleep story narrated by Lila Moss.
Read more →PODDInsulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology
Insulet Corporation has announced the launch of its Omnipod® 5 and Omnipod Discover™ in Spain, marking a significant step in expanding access to its tubeless diabetes management technology. This launch is part of Insulet's strategy to accelerate its global growth and enhance the lives of individuals with diabetes. The introduction of these products aims to provide more patients with innovative solutions for diabetes care.
Read more →PODDInsulet to Announce Second Quarter 2026 Financial Results on August 5, 2026
Insulet Corporation is set to announce its financial results for the second quarter of 2026 on August 5, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and stakeholders are expected to review the results for insights into the company's performance.
Read more →PODDInsulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
Insulet has announced the appointment of Jonathan J. Mazelsky to its Board of Directors. This move is part of the company's strategy to enhance its leadership team. Further details about Mazelsky's background or the implications of this appointment were not provided in the announcement.
Read more →PODD▼ -5.1%on this news
Insulet to Participate in William Blair 46th Annual Growth Stock Conference
Insulet Corporation is set to participate in the William Blair 46th Annual Growth Stock Conference. The event will provide an opportunity for the company to engage with investors and discuss its growth strategies. Further details about the conference and Insulet's presentation have not been disclosed.
Read more →PODDInsulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
Insulet has announced a voluntary medical device correction affecting certain Omnipod® Pods. This correction applies to both the U.S. and international markets, indicating potential safety concerns. The company is addressing issues that may affect the performance and reliability of the devices, which could impact users significantly.
Read more →PODD▼ -9.7%on this news
Insulet Reports First Quarter 2026 Results
Insulet Corporation reported strong financial results for Q1 2026, with revenues of $761.7 million, a 33.9% increase compared to the previous year. The company achieved notable growth in both U.S. and international markets, particularly with its Omnipod product line. Insulet also announced the launch of new products and advancements in automated insulin delivery technology, raising its revenue growth outlook for the year.
Read more →PODD▼ -9.7%on this news
Insulet Reports First Quarter 2026 Results Raises Full Year Total Company Revenue Guidance
Insulet Corporation reported a strong financial performance for the first quarter of 2026, with revenues reaching $761.7 million, up 33.9% from the previous year. The company increased its full-year revenue guidance, citing significant growth in both U.S. and international markets. Noteworthy milestones included the launch of Omnipod 5 in multiple countries and advancements in their automated insulin delivery technology. Overall, Insulet demonstrated robust growth prospects and innovative product enhancements.
Read more →PODDInsulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
Insulet has released its 2025 Sustainability Report, which emphasizes the company's progress in key areas. The report outlines various initiatives aimed at enhancing sustainability and corporate responsibility. However, specific details regarding the report's findings and metrics are not provided in the article.
Read more →PODDInsulet to Participate in BofA Securities 2026 Health Care Conference
Insulet Corporation announced its participation in the BofA Securities 2026 Health Care Conference, scheduled for May 13, 2026. The presentation will showcase Insulet's advancements in insulin delivery technology, particularly the Omnipod product line. The event will be accessible via a live webcast on the company's Investor Relations website.
Read more →PODDPODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky
Insulet Corp. faced a significant stock drop after announcing a voluntary medical device correction for its Omnipod 5 insulin pods, which revealed a design defect causing insulin leakage. This defect has been associated with eighteen serious adverse events, raising concerns about the company's prior knowledge of the issue. Legal investigations are underway regarding potential securities fraud as shareholders seek to address their losses.
Read more →PODDInsulet to Announce First Quarter 2026 Financial Results on May 6, 2026
Insulet Corporation announced it will report its financial results for the first quarter of 2026 on May 6, 2026. The announcement includes details about a conference call scheduled for the same day at 8:00 a.m. Eastern Time. The call will be accessible via the company's Investor Relations website and by phone for both domestic and international callers.
Read more →PODDInsulet Initiates Voluntary Medical Device Correction for Certain Omnipod 5 Pods in the U.S. Medical Device Correction impacts only specific lots of Omnipod 5 Pods Customers can visit omnipod.com check-pods to check lot
Insulet Corporation has announced a voluntary Medical Device Correction for specific lots of its Omnipod 5 Pods in the U.S. due to a manufacturing issue that may lead to insulin leakage. Although this affects 1.5% of annual production, the company has assured that all other Omnipod products remain safe for use. Insulet has notified the FDA and is providing affected customers with replacement Pods at no cost. The company continues to maintain normal operations and does not anticipate any disruptions in product availability.
Read more →PODDInsulet Reports Fourth Quarter and Full Year 2025 Results
Insulet Corporation reported a 31% increase in revenue for both the fourth quarter and full year of 2025, marking its tenth consecutive year of significant growth. The company received board approval for a $350 million increase in share repurchase authorization, demonstrating its strong financial position. Insulet's CEO expressed confidence in the company's ability to expand its market presence and deliver long-term value.
Read more →PODDInsulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care
Insulet Corporation has launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover in the Middle East, including Saudi Arabia, Kuwait, Qatar, and the UAE. This launch aims to address the significant unmet needs of diabetes care in the region. The Omnipod 5 system automates insulin delivery and has demonstrated improved glycemic outcomes. Omnipod Discover offers a user-friendly data management platform for better diabetes management.
Read more →PODDInsulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026
Insulet Corporation will announce its financial results for Q4 and the full year of 2025 on February 18, 2026. The announcement will be made before the market opens, followed by a conference call at 8:00 a.m. ET. The call will be accessible via the company's Investor Relations website and by phone.
Read more →PODDInsulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience
Insulet Corporation has received FDA 510(k) clearance for enhancements to its Omnipod 5 Automated Insulin Delivery System. The updates include a new 100 mg/dL Target Glucose option, allowing for more precise insulin delivery and improved user experience. These advancements aim to strengthen clinical outcomes and simplify the daily management of diabetes for users.
Read more →PODDInsulet Reports Third Quarter 2025 Results Raises Full Year Revenue and Margin Guidance
Insulet Corporation announced positive financial results for the third quarter of 2025, reporting a revenue increase of 29.9% to $706.3 million. The company also raised its revenue and margin guidance for the remainder of the fiscal year, citing strong performances in both U.S. and international sales of its Omnipod product. Notably, U.S. sales grew by 25.6%, while international sales advanced 46.5%. Insulet's gross margin improved to 72.2%, reflecting operational efficiencies.
Read more →PODDInsulet Announces Appointment of Robert L. Huffines to its Board of Directors
Insulet Corporation has announced the appointment of Robert L. Huffines to its Board of Directors, effective October 31, 2025. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase Co., brings over 30 years of experience in advising healthcare companies. His strategic expertise is anticipated to contribute to Insulet's growth and the advancement of its mission to improve diabetes management through innovative technology. Insulet's chairman expressed confidence that Huffines' insights will drive sustainable value for stakeholders.
Read more →PODDInsulet Announces CFO Transition Flavia Pease Appointed Chief Financial Officer ACTON, Mass.-(BUSINESS WIRE)- Insulet Corporation (NASDAQ: PODD) ("Insulet" or the "Company"), the global leader in tu
Insulet Corporation has announced the appointment of Flavia Pease as the new Chief Financial Officer, effective September 30, 2025. She succeeds Ana Maria Chadwick, who will transition into a Senior Advisor role to facilitate a smooth handover. Pease, with a strong background in healthcare finance, has previously served as CFO at Charles River Laboratories and has over 20 years of experience at Johnson & Johnson. The company also anticipates surpassing its revenue growth expectations for the third quarter of 2025, highlighting its continued momentum in the market.
Read more →PODD▲ +9.5%on this news
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency 1 ) Raising Full Year Revenue and Adjusted Operating Margin Guidance
Insulet Corporation reported a 32.9% year-over-year increase in revenue for Q2 2025, totaling $649.1 million, driven mainly by strong sales of its Omnipod products. The company has raised its full-year revenue guidance, reflecting optimism about future growth. Despite a decrease in net income compared to the prior year, improved gross margins and strategic product integrations suggest positive momentum. Insulet's initiatives in sustainability and partnerships further position it favorably in the diabetes management market.
Read more →PODDInsulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency 1 ) Raising Full Year Revenue and Gross Margin Guidance
Insulet Corporation reported a 29% year-over-year revenue increase for Q1 2025, with total revenue reaching $569 million. This performance surpassed the company’s guidance, attributed to the successful global expansion of its Omnipod 5 technology. However, the company experienced a decrease in net income, falling to $35.4 million from $51.5 million in the previous year, despite a rising gross margin of 71.9%. Insulet has raised its full-year revenue and gross margin guidance, indicating confidence in future growth.
Read more →PODDInsulet Appoints Ashley McEvoy President and CEO Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance
Insulet Corporation has appointed Ashley McEvoy as President and CEO, effective immediately. McEvoy brings nearly three decades of healthcare leadership experience to the role, previously serving at Johnson & Johnson. The company anticipates surpassing its first quarter revenue guidance and plans to raise full-year 2025 guidance. Insulet's market leadership in diabetes care is expected to strengthen under McEvoy's leadership, as they continue to pursue innovation and global expansion.
Read more →PODDInsulet Announces Pricing of Senior Notes Due 2033
Insulet Corporation has announced a private placement of $450 million in senior unsecured notes due 2033, with an interest rate of 6.50%. The closing of the placement is expected to occur on March 20, 2025. Proceeds will be primarily used to manage the existing convertible senior notes and for general corporate purposes. The offering targets qualified institutional buyers and non-U.S. persons, adhering to regulatory requirements. This move reflects Insulet's strategy to bolster its financial position while continuing to innovate in the diabetes care sector.
Read more →PODDInsulet Announces Proposed Financing Transactions
Insulet Corporation has announced its intention to offer $450 million in senior unsecured notes due 2033 in a private placement. These funds are intended to finance the repayment of existing convertible senior notes and cover various corporate expenses. Additionally, Insulet plans to amend its revolving credit agreement to extend its maturity and increase credit commitments. However, both the note offering and credit agreement amendments are subject to market conditions.
Read more →PODDInsulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year Represents 9th Consecutive Year of 20% or More Constant Currency 1 Revenue Growth Annual Revenue Surpa
Insulet Corporation reported strong financial results for both the full year and fourth quarter of 2024, highlighting a 22% increase in revenue, exceeding $2 billion for the first time. The Omnipod product line saw significant growth, especially internationally, contributing to the company's overall success. However, operating income for the fourth quarter decreased despite positive revenue trends, affected by prior stocking dynamics. The company maintains a positive outlook for 2025, expecting continued revenue growth.
Read more →PODDInsulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court Jury awards $452 million in damages ACTON, Mass. - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global l
Insulet Corporation has won a significant legal victory against EOFlow Co. in a U.S. District Court, where a jury awarded Insulet $452 million in damages for the misappropriation of its trade secrets. The court found in favor of Insulet after a four-week trial that confirmed EOFlow's willful and malicious actions against the company's intellectual property. Insulet's CEO expressed satisfaction with the ruling, emphasizing the importance of protecting their innovative technology in insulin delivery solutions.
Read more →PODDInsulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency 1 ) Raising Full Year Revenue and Margin Guidance
Insulet Corporation reported a substantial revenue increase of 26% for the third quarter of 2024, exceeding previous guidance. The company attributes this growth to the success of its Omnipod products, including the newly FDA-approved Omnipod 5 for type 2 diabetes. Additionally, Insulet raised its full-year revenue guidance, reflecting positive market performance. The company also reported improvements in operating and net income margins, highlighting its strong position in the diabetes management sector.
Read more →PODDInsulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue, Gross Margin and Operating Margin Guidance
Insulet Corporation reported a 23.2% increase in revenue for the second quarter of 2024, reaching $488.5 million. The company raised its full-year guidance for revenue, gross margin, and operating margin in light of strong performance across all product lines, particularly the Omnipod. Despite a decrease in drug delivery revenue and an inventory-related charge impacting margins, Insulet's leadership expressed confidence in continued growth driven by product innovations and market demand. The company also noted the successful commercial launch of Omnipod 5 integrated with various continuous glucose monitoring systems.
Read more →PODDInsulet Reports Preliminary Second Quarter 2024 Revenue Results Second Quarter Revenue Increased 23% Year-Over-Year Raising Full Year 2024 Total Omnipod Revenue Outlook
Insulet Corporation reported preliminary revenue results for the second quarter of 2024, revealing a significant year-over-year increase of 23%, with total revenue reaching $488 million. The Omnipod product line specifically performed well, achieving a revenue boost of 26% and contributing importantly to the overall financial performance. Insulet plans to increase its full-year 2024 revenue outlook, reflecting confidence in continued growth driven by demand for the Omnipod 5 system. Full financial results will be disclosed on August 8, 2024, during a scheduled conference call.
Read more →PODDInsulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue and Operating Margin Guidance
Insulet Corporation (NASDAQ: PODD) reported a 23.3% increase in first-quarter 2024 revenue, reaching $441.7 million, which exceeded earlier guidance. The company's Omnipod revenue rose by 21.1%, with significant contributions from U.S. sales. Insulet also raised its full-year revenue and operating margin guidance, reflecting strong demand for their products and successful market strategies. Despite positive financial outcomes, the company continues to face challenges in its drug delivery segment.
Read more →PODDInsulet Appoints Ana Maria Chadwick as Chief Financial Officer
Insulet Corporation has appointed Ana Maria Chadwick as Chief Financial Officer effective April 22, 2024, following an extensive search. Chadwick, currently CFO at Pitney Bowes, brings 30 years of financial expertise, having held leadership roles in both Pitney Bowes and GE. Her appointment is intended to strengthen Insulet's financial foundation as the company continues to pursue growth in the diabetes management field. Interim CFO Lauren Budden will resume her role as Chief Accounting Officer after successfully guiding the company during the transition period.
Read more →PODDInsulet Reports Full Year 2023 Revenue Increase of 30% (30% constant currency 1 ) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% constant currency) Represents 8th Consecutive Year of 20% or More Cons
Insulet Corporation reported a 30% revenue increase for the full year 2023, reaching $1.7 billion, driven by strong demand for its Omnipod insulin pumps. The fourth quarter also demonstrated robust growth, with revenues up 38% year-over-year. Notably, U.S. Omnipod revenue surged by 41.4%, contributing significantly to overall performance. The company anticipates continued growth in 2024, although it has highlighted possible revenue impacts from a new ERP system implementation.
Read more →PODDInsulet Announces Changes to Board of Directors with Retirements and New Appointments Flavia Pease and Timothy Stonesifer to join Board of Directors Shacey Petrovic and Corinne Nevinny to retire from the Board at the Com
Insulet Corporation announced new appointments to its Board of Directors effective January 18, 2024, with Flavia Pease and Timothy Stonesifer joining the board. They replace Shacey Petrovic and Corinne Nevinny, who will retire at the Company's 2024 Annual Meeting in May. The Chairman expressed enthusiasm for the new members, highlighting their extensive experience and contribution to advancing Insulet's commitment to excellence. The company acknowledges the departing members for their significant contributions to its mission of improving diabetes management.
Read more →PODDInsulet Reports Third Quarter 2023 Revenue Increase of 27% Year-Over-Year (25% Constant Currency 1 ) Raised Full Year Revenue Guidance to a Range of 26% to 27%, including Total Omnipod of 29% to 30%
Insulet Corporation reported a 27% increase in third-quarter revenue for 2023, reaching $432.7 million. The company raised its full-year revenue guidance to a growth range of 26% to 27%, driven by strong demand for its Omnipod insulin pump technology. The gross margin also improved significantly, highlighting better operational efficiency. However, the Drug Delivery segment experienced a revenue decline of 27.2%, which could pose challenges going forward.
Read more →PODDInsulet Announces CFO Transition Reaffirms Guidance for Third Quarter and Fiscal Year 2023
Insulet Corporation has announced the resignation of CFO Wayde McMillan, who will be joining 3M as CFO of its Healthcare division. Lauren Budden, currently the Group Vice President and Chief Accounting Officer, will serve as Interim CFO until a permanent successor is found. The company has reaffirmed its revenue guidance for the third quarter and the full fiscal year of 2023, indicating strong financial stability moving forward.
Read more →PODD▼ -8.6%on this news
Insulet Reports Second Quarter 2023 Revenue Increase of 32% Year-Over-Year (32% Constant Currency 1 )
Insulet Corporation reported a strong financial performance for the second quarter of 2023, with revenues rising 32.4% year-over-year to $396.5 million. Notable growth was seen in both U.S. and international Omnipod sales, contributing to the overall success. The company is optimistic about future growth, raising its revenue guidance for the year to 22%-25%. They have also launched Omnipod 5 in the UK and made strides with their FDA submissions, signaling continued innovation in the diabetes management market.
Read more →PODD▼ -8.6%on this news
UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS INSULET CORPORATION, Plaintiff , Case No. 1 23-cv-11780 v. JURY TRIAL DEMANDED EOFLOW CO., LTD. EOFLOW, INC. FLEX, LTD. FLEXTRONICS CORPORATION FLEXTRONICS MEDICAL S
Insulet Corporation has filed a lawsuit against EOFlow Co., Ltd. and associated companies for the alleged theft of their proprietary technology related to insulin delivery devices. The complaint claims that EOFlow copied Insulet's groundbreaking Omnipod System by hiring former key employees and utilizing secret manufacturing processes. Insulet's legal action highlights concerns over intellectual property rights and competition in the diabetes management device market. This case underscores the challenges faced by innovators in protecting their technological advancements from infringement.
Read more →PODDInsulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency 1 )
Insulet Corporation reported a revenue increase of 21.2% for Q1 2023, amounting to $358.1 million, primarily driven by a 32.7% growth in Total Omnipod sales. Significantly, U.S. Omnipod revenue rose by 48.8%, reflecting strong demand. Despite this growth, the company faced challenges with a substantial decline in Drug Delivery revenue and a decrease in gross margin. Insulet also received FDA clearance for its new Omnipod GOTM and is preparing for international product launches.
Read more →PODDInsulet Announces New Organizational Structure to Drive Further Growth Structured to Accelerate Innovation and Commercialization Priorities Creates New Roles to Oversee Product End-to-End Customer Experience and Technolo
Insulet Corporation has announced a new organizational structure to enhance its innovation and commercialization efforts. This restructuring includes the creation of new leadership roles, effective July 1, 2023, aimed at improving product management and customer experience. The company recently launched the Omnipod 5 Automated Insulin Delivery System in the U.S. and is preparing for an international launch. This initiative supports Insulet's goal to strengthen its commercial capabilities and continue expanding its global presence in diabetes management.
Read more →PODDInsulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency 1 ) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (24% constant currency) Represents 7th Consecutive Year of 20% or More Cons
Insulet Corporation reported a strong financial performance for the full year 2022, with revenues reaching $1.3 billion, marking an 18.8% increase compared to 2021. The company's Omnipod product line significantly contributed to this growth, with total revenue from Omnipod rising by 23.4%. Despite the positive overall results, Insulet faced challenges in its Drug Delivery segment, which experienced a notable 34.2% decrease in revenue. Looking ahead, Insulet expects to continue its momentum, projecting revenue growth of 14% to 19% for 2023.
Read more →PODDInsulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod 5 Controller
Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod 5 Controller ACTON, Mass.- November 14, 2022 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), today announced a Medical Device Correction for the Omnipod 5 Automated Insulin Delivery Sys
Read more →PODDInsulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency 1 )
Insulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency1) ACTON, Mass. - November 3, 2022 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of produ
Read more →PODDInsulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency 1 ) Recently Launched U.S. Full Market Release for Omnipod 5 - Now Available through Retail Pharmacies
Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1) Recently Launched U.S. Full Market Release for Omnipod 5 - Now Available through Retail Pharmacies ACTON, Mass. - August 4, 2022 - Insulet Corporation (NASDAQ PODD) (Insulet or
Read more →PODD▼ -9.4%on this news
Insulet Announces CEO Transition Director Jim Hollingshead to Succeed Shacey Petrovic as President and
Insulet Announces CEO Transition Director Jim Hollingshead to Succeed Shacey Petrovic as President and CEO, Effective June 1, 2022 Petrovic and Hollingshead to Continue as Members of Insulet's Board of Directors ACTON, Mass. - May 5, 2022 - Insulet Corporation (NASDAQ PODD) (I
Read more →PODD▼ -8.1%on this news· ran to -23% by day 3shared move
Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
Insulet Reports First Quarter 2022 Revenue Increase of 17% ACTON, Mass. - May 5, 2022 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the
Read more →PODDInsulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year Represents 6th Consecutive Year of Over 20% Revenue Growth Annual Revenue Surpasses $1 Billion Omnipod
Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year Represents 6th Consecutive Year of Over 20% Revenue Growth Annual Revenue Surpasses $1 Billion Omnipod 5 Automated Insulin Delivery System Receives U.S. FDA C
Read more →PODDInsulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine
Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine ACTON, Mass. - Feb. 7, 2022 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today a
Read more →PODD▲ +18.4%on this news· ran to +30% by day 3
Insulet Announces FDA Clearance of its Omnipod 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control ACTON, MA
Insulet Announces FDA Clearance of its Omnipod 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control ACTON, MA - January 28, 2022 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with
Read more →PODDInsulet Reports Third Quarter 2021 Revenue Increase of 18% Year-Over-Year ACTON, MA
Insulet Reports Third Quarter 2021 Revenue Increase of 18% ACTON, MA - November 4, 2021 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for t
Read more →PODDInsulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford ACTON, MA
Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford ACTON, MA - October 18, 2021 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnip
Read more →PODDInsulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year ACTON, MA
Insulet Reports Second Quarter 2021 Revenue Increase of 16% ACTON, MA - August 5, 2021 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for th
Read more →PODDInsulet Reports First Quarter 2021 Revenue Increase of 27% Year-Over-Year ACTON, MA
Insulet Reports First Quarter 2021 Revenue Increase of 27% ACTON, MA - May 6, 2021 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the th
Read more →PODDInsulet Announces Pricing of New Senior Secured Credit Facilities
Insulet Announces Pricing of New Senior Secured Credit Facilities ACTON, Mass., April 29, 2021 Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced the pricing of a
Read more →PODDInsulet Announces Launch of Syndication of New Credit Facilities
Insulet Announces Launch of Syndication of New Credit Facilities ACTON, Mass., April 19, 2021 Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that it has launch
Read more →PODDInsulet Reports Full Year 2020 Revenue Increase of 23% and Fourth Quarter 2020 Revenue Increase of 18% Year-Over-Year Represents 5th Consecutive Year of Over 20% Revenue Growth Record Quarterly Revenue ACTON, MA
Insulet Reports Full Year 2020 Revenue Increase of 23% and Fourth Quarter 2020 Revenue Increase of 18% Year-Over-Year Represents 5th Consecutive Year of Over 20% Revenue Growth Record Quarterly Revenue ACTON, MA - February 23, 2021 - Insulet Corporation (NASDAQ PODD) (Insulet
Read more →PODDInsulet Reports Third Quarter 2020 Revenue Increase of 22% Year-Over-Year Includes Total Omnipod Revenue Growth of 20%
Insulet Reports Third Quarter 2020 Revenue Increase of 22% Year-Over-Year Includes Total Omnipod Revenue Growth of 20% ACTON, Mass. - November 4, 2020 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Om
Read more →PODDInsulet Appoints Wayne A. I. Frederick, M.D., to Board of Directors
Insulet Appoints Wayne A. I. Frederick, M.D., to Board of Directors ACTON, Mass.- Oct. 20, 2020 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), today
Read more →PODDInsulet Reports Second Quarter 2020 Revenue Increase of 28% Year-Over-Year Includes Total Omnipod Revenue Growth of 26%
Insulet Reports Second Quarter 2020 Revenue Increase of 28% Year-Over-Year Includes Total Omnipod Revenue Growth of 26% ACTON, Mass. - August 6, 2020 - Insulet Corporation (NASDAQ PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omn
Read more →PODDInsulet Corporation Announces Pricing of $500 Million Public Offering of Common Stock
Insulet Corporation Announces Pricing of $500 Million Public Offering of Common Stock ACTON, Mass. - May 12, 2020 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), a global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnip
Read more →PODDInsulet Corporation Announces Plans for Public Offering of Common Stock
Insulet Corporation Announces Plans for Public Offering of Common Stock ACTON, Mass. - May 12, 2020 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), a global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), to
Read more →PODDInsulet Reports First Quarter 2020 Revenue Increase of 24% Year-Over-Year Includes Total Omnipod Revenue Growth of 33% ACTON, Mass.--(BUSINESS WIRE)
Insulet Reports First Quarter 2020 Revenue Increase of 24% Year-Over-Year Includes Total Omnipod Revenue Growth of 33% ACTON, Mass.--(BUSINESS WIRE)--May 7, 2020--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology
Read more →PODDInsulet Reports Full Year 2019 Revenue of $738.2 Million, an Increase of 31%, and Fourth Quarter 2019 Revenue of $209.4 Million, an Increase of 27% Year-Over-Year ACTON, Mass.--(BUSINESS WIRE)
Insulet Reports Full Year 2019 Revenue of $738.2 Million, an Increase of 31%, and Fourth Quarter 2019 Revenue of $209.4 Million, an Increase of 27% Year-Over-Year ACTON, Mass.--(BUSINESS WIRE)--February 25, 2020--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the g
Read more →PODDInsulet Reports Third Quarter 2019 Revenue of $192 Million, an Increase of 27% Year-Over-Year ACTON, Mass.--(BUSINESS WIRE)
Insulet Reports Third Quarter 2019 Revenue of $192 Million, an Increase of 27% Year-Over-Year ACTON, Mass.--(BUSINESS WIRE)--November 5, 2019--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insu
Read more →PODDInsulet Announces Pricing of Convertible Senior Notes Due 2026
Insulet Announces Pricing of Convertible Senior Notes Due 2026 ACTON, Mass., September 4, 2019 Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), has priced a priv
Read more →PODDInsulet Announces Private Offering of Convertible Senior Notes
Insulet Announces Private Offering of Convertible Senior Notes ACTON, Mass., September 3, 2019 Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), today announced i
Read more →PODDInsulet Reports Second Quarter 2019 Revenue of $177 Million, an Increase of 43% Year-Over-Year ACTON, Mass.--(BUSINESS WIRE)
Insulet Reports Second Quarter 2019 Revenue of $177 Million, an Increase of 43% Year-Over-Year ACTON, Mass.--(BUSINESS WIRE)--August 5, 2019--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insul
Read more →PODDInsulet Appoints Jim Hollingshead to Board of Directors
Insulet Appoints Jim Hollingshead to Board of Directors ACTON, Mass. - July 31, 2019 -- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), today announced
Read more →PODDInsulet Reports First Quarter 2019 Revenue of $159.6 Million, an Increase of 29% Year-Over-Year Commenced Pod Production at U.S. Manufacturing Facility and Initiated Full U.S. Commercial Launch of Omnipod DASH ACTON, Mas
Reports First Quarter 2019 Revenue of $159.6 Million, an Increase of 29% Pod Production at U.S. Manufacturing Facility and Initiated Full U.S. Commercial Launch of Omnipod DASH ACTON, Mass.--(BUSINESS WIRE)--May 2, 2019--Insulet Corporation (NASDAQ: PODD) (Insulet or the Comp
Read more →PODDInsulet Reports Fourth Quarter 2018 Revenue of $164.9 Million, Up 26% Year-Over-Year, and Full Year 2018 Revenue of $563.8 Million, Up 22% ACTON, Mass.--(BUSINESS WIRE)
Reports Fourth Quarter 2018 Revenue of $164.9 Million, Up 26% Year-Over-Year, and Full Year 2018 Revenue of $563.8 Million, Up 22% ACTON, Mass.--(BUSINESS WIRE)--February 25, 2019--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insu
Read more →PODDInsulet Appoints Corinne Nevinny to Board of Directors ACTON, Mass.--(BUSINESS WIRE)
Appoints Corinne Nevinny to Board of Directors ACTON, Mass.--(BUSINESS WIRE)--January 28, 2019--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), toda
Read more →PODDInsulet Appoints Wayde McMillan Chief Financial Officer ACTON, Mass.--(BUSINESS WIRE)
Appoints Wayde McMillan Chief Financial Officer ACTON, Mass.--(BUSINESS WIRE)--January 7, 2019--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), toda
Read more →PODDInsulet Reports Third Quarter 2018 Revenue of $151.1 Million, Up 24% Year-Over-Year, and Gross Margin Over 67%, Up 700 Basis Points Achieved Both Positive Operating and Net Income for the First Time in Insulet's History
Reports Third Quarter 2018 Revenue of $151.1 Million, Up 24% Year-Over-Year, and Gross Margin Over 67%, Up 700 Basis Points Both Positive Operating and Net Income for the First Time in Insulet's BILLERICA, Mass.--(BUSINESS WIRE)--November 1, 2018--Insulet Corporation (NASDAQ:
Read more →PODDInsulet Announces Shacey Petrovic, President and COO, Promoted to
Insulet Announces Shacey Petrovic, President and COO, Promoted to CEO, Effective January 1, 2019; Patrick Sullivan Will Retire as Chairman and CEO at the End of 2018 Timothy Scannell Will Become Chairman of the Board BILLERICA, Mass.--(BUSINESS WIRE)--September 10, 2018--Insule
Read more →PODDInsulet Reports Second Quarter 2018 Revenue of $124.3 Million, Up 13% Year-Over-Year, and Gross Margin of 66%, Up 710 Basis Points Full Year 2018 Expected Revenue Growth Revised to 18% to 21% Third Quarter Expected Reven
Reports Second Quarter 2018 Revenue of $124.3 Million, Up 13% Year-Over-Year, and Gross Margin of 66%, Up 710 Basis Points Year 2018 Expected Revenue Growth Revised to 18% to 21% Quarter Expected Revenue Growth of 19% to 24% BILLERICA, Mass.--(BUSINESS WIRE)--August 2, 2018--
Read more →PODDInsulet Reports First Quarter 2018 Revenue of $123.6 Million, Up 21% Year-Over-Year, and Gross Margin of 61.4%, Up 300 Basis Points, Exceeding Expectations Increases Full Year 2018 Expected Revenue Growth to 22% to 25% o
Reports First Quarter 2018 Revenue of $123.6 Million, Up 21% Year-Over-Year, and Gross Margin of 61.4%, Up 300 Basis Points, Exceeding Expectations Full Year 2018 Expected Revenue Growth to 22% to 25% on Strength in Second Quarter Expected Revenue Growth of 18% to 22% BILLER
Read more →PODDInsulet Reports Fourth Quarter Revenue of $130.5 Million, Up 26%, and Gross Margin Up 210 Basis Points, Exceeding Expectations Full Year 2017 Revenue of $463.8 Million, Up 26%, and Gross Margin Up 230 Basis Points Full Y
Reports Fourth Quarter Revenue of $130.5 Million, Up 26%, and Gross Margin Up 210 Basis Points, Exceeding Expectations Year 2017 Revenue of $463.8 Million, Up 26%, and Gross Margin Up 230 Year 2018 Expected Revenue Growth of 21% to 25% BILLERICA, Mass.--(BUSINESS WIRE)--Febru
Read more →PODDInsulet Reports Third Quarter 2017 Financial Results Third Quarter Revenue of $121.8 Million, Up 28% Year-Over-Year, Exceeds Expectations; Gross Margin Improves to 60.5% Insulet Raises Full Year 2017 Revenue Guidance to
Reports Third Quarter 2017 Financial Results Quarter Revenue of $121.8 Million, Up 28% Year-Over-Year, Exceeds Expectations; Gross Margin Improves to 60.5% Raises Full Year 2017 Revenue Guidance to a Range of $456 to $459 million, Up from $440 to $450 Million, Representing Gr
Read more →PODDInsulet Corporation Appoints Michael R. Minogue and James C. Mullen to Board of Directors BILLERICA, Mass.--(BUSINESS WIRE)
Insulet Corporation Appoints Michael R. Minogue and James C. Mullen to Board of Directors BILLERICA, Mass.--(BUSINESS WIRE)--August 10, 2017--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod Insulin Mana
Read more →PODDInsulet Reports Second Quarter 2017 Financial Results Second Quarter Revenue of $109.8 Million, Up 26% Year-Over-Year, Exceeds Expectations; Gross Margin Improves to 58.9% Insulet Raises Full Year 2017 Revenue Guidance t
Insulet Reports Second Quarter 2017 Financial Results Second Quarter Revenue of $109.8 Million, Up 26% Year-Over-Year, Exceeds Expectations; Gross Margin Improves to 58.9% Insulet Raises Full Year 2017 Revenue Guidance to a Range of $440 to $450 million, Up from $425 to $440 Mi
Read more →PODDInsulet to Assume Distribution and Commercial Support for Its Omnipod System in Europe Direct Distribution Supports Strong and Growing European Customer Base Further Strengthens Company's Financial Outlook BILLERICA, Mas
Insulet to Assume Distribution and Commercial Support for Its Omnipod System in Europe Direct Distribution Supports Strong and Growing European Customer Base Further Strengthens Company's Financial Outlook BILLERICA, Mass.--(BUSINESS WIRE)--July 20, 2017--Insulet Corporation (
Read more →PODDInsulet Reports First Quarter 2017 Financial Results First Quarter Revenue of $101.7 Million, up 25% Year-Over-Year, Exceeds Expectations Gross Margin Improves to 58.4% Insulet Raises Mid-Point of Full Year 2017 Revenue
Reports First Quarter 2017 Financial Results Quarter Revenue of $101.7 Million, up 25% Year-Over-Year, Exceeds Margin Improves to 58.4% Raises Mid-Point of Full Year 2017 Revenue Guidance, Expecting Growth of 18%, and Introduces Second Quarter Growth Expectation of 21% BILLE
Read more →PODDInsulet Reports Fourth Quarter and Full Year 2016 Financial Results Fourth Quarter Revenue of $103.6 Million, up 24% Year-Over-Year; Full Year 2016 Revenue of $367.0 Million, up 39% Year-Over Year, Exceeds Expectations F
Reports Fourth Quarter and Full Year 2016 Financial Results Quarter Revenue of $103.6 Million, up 24% Year-Over-Year; Full Year 2016 Revenue of $367.0 Million, up 39% Year-Over Year, Exceeds Expectations Quarter Gross Margin Improves to 58.8%; Full Year 2016 Gross Margin Expe
Read more →PODDInsulet Reports Third Quarter 2016 Financial Results Third Quarter Revenue of $94.9 Million, up 33% Year-Over-Year, Exceeds Expectations Gross Margin Improves to 58.6% Company Raises Full Year 2016 Revenue Guidance to a
Reports Third Quarter 2016 Financial Results Quarter Revenue of $94.9 Million, up 33% Year-Over-Year, Exceeds Margin Improves to 58.6% Raises Full Year 2016 Revenue Guidance to a Range of $362 to $365 million, from $345 to $355 million; Approximately 38% Year-Over-Year BILLE
Read more →PODDInsulet Announces Board and Management Changes Patrick Sullivan Elected Chairman of the Board Jessica Hopfield, PhD, Assumes Role of Lead Independent Director Shacey Petrovic Promoted to President and Chief Operating Off
Announces Board and Management Changes Sullivan Elected Chairman of the Board Hopfield, PhD, Assumes Role of Lead Independent Director Petrovic Promoted to President and Chief Operating Officer Levangie Announces Retirement BILLERICA, Mass.--(BUSINESS WIRE)--October 19, 2016
Read more →PODDPatient Protection and Affordable Care Act . The Patient Protection and Affordable Care Act ("ACA") enacted significant changes to the provision of and payment for healthcare in the United States. Under the ACA and relat
We are primarily engaged in the development, manufacturing and sale of our proprietary OmniPod Insulin Management System (the "OmniPod System"), an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The OmniPod Syst
Read more →PODDInsulet Reports Second Quarter 2016 Financial Results Second Quarter Revenue of $87.3 Million, up 44% Year-Over-Year, Exceeds Expectations Company Raises Mid-Point of Full Year 2016 Revenue Guidance by $10 Million Gross
Reports Second Quarter 2016 Financial Results Quarter Revenue of $87.3 Million, up 44% Year-Over-Year, Exceeds Raises Mid-Point of Full Year 2016 Revenue Guidance by $10 Million Margin Improves to 57.8% BILLERICA, Mass.--(BUSINESS WIRE)--August 3, 2016--Insulet Corporation (
Read more →PODDInsulet Reaffirms Second Quarter and Full Year 2016 Guidance
Insulet Reaffirms Second Quarter and Full Year 2016 Guidance BILLERICA, Mass., May 3, 2016 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its OmniPod Insulin Management System (OmniPod System), tod
Read more →PODDInsulet Reports First Quarter 2016 Financial Results First Quarter Revenue of $81.2 Million, up 69% Year-Over-Year, Exceeds Expectations BILLERICA, MA
Insulet Reports First Quarter 2016 Financial Results First Quarter Revenue of $81.2 Million, up 69% Year-Over-Year, Exceeds Expectations BILLERICA, MA - April 28, 2016 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology
Read more →PODDInsulet Reports Fourth Quarter and Full Year 2015 Financial Results Fourth Quarter Revenue of $100.1 Million, up 38% Year-Over-Year, Exceeds Expectations Insulet Expects Full Year 2016 Pro Forma Revenue Growth of Approxi
Insulet Reports Fourth Quarter and Full Year 2015 Financial Results Fourth Quarter Revenue of $100.1 Million, up 38% Year-Over-Year, Exceeds Expectations Insulet Expects Full Year 2016 Pro Forma Revenue Growth of Approximately 30% BILLERICA, MA - February 25, 2016 - Insulet Co
Read more →PODDInsulet Appoints David A. Lemoine to Board of Directors New Independent Director Brings Extensive Accounting and Financial Reporting Expertise BILLERICA, MA.
Insulet Appoints David A. Lemoine to Board of Directors New Independent Director Brings Extensive Accounting and Financial Reporting Expertise BILLERICA, MA. - February 9, 2016 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump te
Read more →PODDInsulet to Divest Neighborhood Diabetes Supplies Business Signs definitive agreement to sell Neighborhood Diabetes to Liberty Medical Transaction Enhances Insulet's Focus on its Faster Growing Innovative Products
Insulet to Divest Neighborhood Diabetes Supplies Business Signs definitive agreement to sell Neighborhood Diabetes to Liberty Medical Transaction Enhances Insulet's Focus on its Faster Growing Innovative Products BILLERICA, Mass., February 2, 2016 - Insulet Corporation (NASDAQ
Read more →PODDInsulet Reports Third Quarter 2015 Financial Results Revenue of $87.3 Million Exceeds Expectations; Year-over-Year Revenue Growth in all Four Product Lines Company Raises Full Year 2015 Revenue Guidance BILLERICA, MA
Insulet Reports Third Quarter 2015 Financial Results Revenue of $87.3 Million Exceeds Expectations; Year-over-Year Revenue Growth in all Four Product Lines Company Raises Full Year 2015 Revenue Guidance BILLERICA, MA - November 5, 2015 - Insulet Corporation (NASDAQ: PODD), th
Read more →PODDInsulet Reports Second Quarter 2015 Financial Results Revenue of $75.6 Million Exceeds Expectations; Strong Momentum Heading into Second Half of Year Company Reaffirms Full Year 2015 Guidance BILLERICA, MA
Insulet Reports Second Quarter 2015 Financial Results Revenue of $75.6 Million Exceeds Expectations; Strong Momentum Heading into Second Half of Year Company Reaffirms Full Year 2015 Guidance BILLERICA, MA - August 12, 2015 - Insulet Corporation (NASDAQ: PODD), the leader in
Read more →PODDInsulet Provides Update Regarding Release of Second Quarter Results Company Reiterates Preliminary Second Quarter 2015 Revenue Results and Revenue Guidance for Third Quarter and Full Year 2015 BILLERICA, MA
Insulet Provides Update Regarding Release of Second Quarter Results Company Reiterates Preliminary Second Quarter 2015 Revenue Results and Revenue Guidance for Third Quarter and Full Year 2015 BILLERICA, MA - August 10, 2015 - Insulet Corporation (NASDAQ: PODD), the leader in
Read more →PODDInsulet Reports Preliminary Second Quarter 2015 Revenue Results Company Anticipates Second Quarter Revenue of $75.6 Million, Exceeding Expectations Company Reaffirms Full Year 2015 Revenue Guidance of $305 to $320 millio
Insulet Reports Preliminary Second Quarter 2015 Revenue Results Company Anticipates Second Quarter Revenue of $75.6 Million, Exceeding Expectations Company Reaffirms Full Year 2015 Revenue Guidance of $305 to $320 million Company Postpones Release of Full Second Quarter 2015 R
Read more →PODDInsulet Appoints Jessica Hopfield, PhD, to Board of Directors Addition Strengthens the Board's Healthcare and Diabetes Expertise BILLERICA, MA
Insulet Appoints Jessica Hopfield, PhD, to Board of Directors Addition Strengthens the Board's Healthcare and Diabetes Expertise BILLERICA, MA, July 28, 2015 - Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod Insulin Management
Read more →PODDInsulet Announces Organizational Changes Focus on Operational Excellence BILLERICA, MA
Insulet Announces Organizational Changes Focus on Operational Excellence BILLERICA, MA- June 30, 2015 - Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod Insulin Management System, today announced a series of organizational chan
Read more →Competitive Position
How PODD ranks across every disease it competes inCompetitive Position is a premium feature
See how PODD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial